Under construction – not a live service
Sign in
Not yet taking people in Hong KongNo phase

Fitness and Lifestyle Program to Prevent Osteoporosis and Sarcopenia in Middle-Aged Adults

Tests a fitness and lifestyle program to prevent bone and muscle loss in adults.

Key facts

Who runs it
The University of Hong Kong
Where
Hong Kong, Hong KongSee the site
Trial code
Registry title
Osteoporosis and Sarcopenia Prevention in Middle-Aged Population
Status
Not yet recruiting
People taking part
8,336 people, planned
Started
1 Jun 2026
Expected to end
31 May 2036
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Intervention Group
  • Control Group
Record updated
28 May 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for women and men aged 40-60 at low to moderate risk of osteoporosis, to test a fitness and lifestyle program that aims to prevent fractures, osteoporosis and sarcopenia.

Age
40 to 60 years
Sex
Women and men
Disease stage
Low to moderate risk of osteoporosis, for example no earlier fragility fracture. Well-controlled conditions such as hypertension, diabetes or pre-diabetes are allowed.

Main reasons for not taking part

  • Serious or uncontrolled medical illness that makes aerobic exercise risky, such as active ischemic heart disease, unstable angina or uncontrolled hypertension
  • More than 4 hours of intensive sports per week

The registry criteria, word for word

Show all 5 criteriaShow less

Who can take part

  • General Population: Women and men aged 40-60 years, defined as age groups where the rate of injuries were still relatively lower, thus considered as a low to moderate risk cohort for osteoporosis
  • Risk profile: Targets a low to moderate risk cohort for osteoporosis (e.g., as defined by no prior fragility fracture and questionnaire). This aligns with the study's primary prevention objective
  • Individuals with well-controlled comorbidities like hypertension, diabetes, or pre-diabetes can be included in the study program. Exercise and healthy nutritional diets can also help treat their existing health conditions

Who cannot take part

  • Significant comorbidities: Individuals with existing (e.g., severe or uncontrolled) medical illness, due to risk to aerobic exercise. This includes, but is not limited to, active ischemic heart disease, unstable angina, uncontrolled hypertension, or other conditions as determined by study physicians
  • High baseline activity: Individuals who have engaged in >4 hours intensive sports per week will be excluded. This population is deemed to be at very low risk, thus would likely derive minimal additional benefit from the intervention, and their inclusion could represent inefficient use of finite resources (e.g., DEXA scanning services)

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 40 and 60 years old?

Where in Hong Kong

  • Queen Mary Hospital, The University of Hong Kong, Hong Kong,Hong Kong, Hong KongContact: Christian FANGNo longer taking part

About the trial

What the trial wants to find out

This initiative is designed to yield substantial and multi-level benefits for the Hong Kong community by pioneering a transformative model of preventive healthcare. It represents the largest randomized controlled trial for osteoporosis and sarcopenia prevention in the region, adopting a comprehensive approach to fracture prevention through innovative fitness, lifestyle, and digital strategies.

Read full original descriptionShow less

The study's primary objective is to evaluate the efficacy of preventing fractures, osteoporosis, and sarcopenia through an incentivized program of fitness and lifestyle modifications in adults aged 40-60. The secondary objectives include: (1) to validate the use of simple, low-cost measures (grip strength and InBody body composition analysis) as reliable proxy indicators for osteoporosis and sarcopenia risk relative to the gold-standard DEXA scan; (2) to develop a formal, standardized clinical protocol for early detection and prevention, including specified DEXA anatomical measurement sites, for use by healthcare professionals in primary and community care settings; (3) to assess changes in exercise behavior, musculoskeletal health, physical function, health literacy, and participant engagement with the digital (AI chatbot) support system; (4) to analyze the cost-effectiveness of the intervention compared to standard care or pharmacological treatment, including an assessment of healthcare utilization and Quality-Adjusted Life Years (QALYs).

After baseline screening and consent, participants are randomly assigned to one of two groups (1:1 ratio) with intention-to-treat principles. The Control Group will receive passive, static support. This involves participating in one initial FUN Day, receiving standard exercise videos, using a passive chatbot for data reporting, undergoing start and end DEXA scans (which require a co-payment), completing a 3-month assessment, and receiving souvenirs at the study start and end. Meanwhile, the Intervention Group will receive active, dynamic support designed to build and reinforce healthy habits. This involves participating in the initial FUN Day, a reinforcement FUN Day at 2 months, nine mandatory structured exercise touchpoints, using an active chatbot with reminders, feedback, and gamification, undergoing start and end DEXA scans (which require a co-payment), completing a 3-month assessment, and receiving ongoing incentives and souvenirs at multiple points. Therefore, researchers will compare between the control and intervention groups to see if intervention can prevent osteoporosis and sarcopenia at a population level.

All participants will undergo a series of assessments at specific timepoints. This includes two DEXA scans (at the study start and in the fourth year, requiring a participant co-payment), InBody composition analysis, and physical health assessments (e.g., grip strength, balance, cardiovascular fitness). These assessments will be performed at baseline (during the first FUN Day), 3 months, 12 months, 24 months, and 36 months. A long-term follow-up will continue for up to 10 years to monitor adverse health events such as falls and fractures. Participants will also complete questionnaires via an AI chatbot at baseline, 3 months, and annually during follow-up. The collected data will encompass health literacy (e.g., osteoporosis/sarcopenia knowledge scores), digital engagement (e.g., chatbot responsiveness), and economic outcomes (e.g., incremental cost per Quality-Adjusted Life Year [QALY] gained). Data analysis will employ appropriate statistical methods to compare outcomes between the control and intervention groups across all assessments and timepoints.

The 2 groups in the trial

  • Intervention GroupTreatment being tested

    The intervention group will receive active, dynamic, and sustained support designed to build habits and maintain long-term healthy habits.

  • Control GroupExisting treatment, for comparison

    The control group will receive passive and static support.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Osteoporosis and Sarcopenia Prevention in Middle-Aged Population
Plain-language title
Fitness and Lifestyle Program to Prevent Osteoporosis and Sarcopenia in Middle-Aged AdultsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 13 November 2026.
Fit questions
Built from NCT07611097, who can take part
Record updated
28 May 2026